China’s national consumer‑rights broadcast has put a small Zhengzhou biotech firm at the centre of a widening controversy over so‑called ‘miracle’ exosome products. The NetEase summary of the CCTV 3.15 programme named Zhengzhou Yuanchuang Gene Technology Co., Ltd., and public registry data show the company — founded in 2016 with RMB 22.2m in registered capital — has seen multiple patent applications rejected. The legal representative is listed as Zhao Yan and shareholders include private investment partnerships and regional funds.
Patent filings tied to Yuanchuang that are flagged in public intellectual property records include an immune‑cell cryopreservation solution and freezing method, and a method for preparing skin fibroblasts. The records indicate those applications were rejected, a setback that compounds the reputational damage from being singled out on prime‑time consumer TV. For a small firm whose business scope covers collection, storage, preparation and translational application of stem cells and immune cells, loss of patent protection narrows commercial options and undermines claims of proprietary technical advantage.
The controversy sits at the intersection of genuine scientific promise and rampant commercial hype. Exosomes — tiny extracellular vesicles that mediate cell‑to‑cell signalling — are a fast‑moving area of biomedical research with potential uses in diagnostics and therapeutics. But in China, as elsewhere, that potential has prompted a parallel market of unproven products marketed with sweeping claims. The phrase “万能外泌体” (“万能” meaning “universal” or “miracle”) has become shorthand for therapies and cosmetics promising outsized benefits with limited clinical validation.
China’s regulators and patent examiners apply distinct tests. Patent offices require novelty, inventive step and sufficient technical disclosure; many biotech applications fail when data are thin or the claimed effect is not convincingly demonstrated. Separate regulatory oversight for medical products — administered by the National Medical Products Administration and health authorities at provincial and municipal levels — scrutinises clinical trial design, advertising and the provision of medical services. A high‑profile consumer broadcast often precipitates follow‑up inspections and administrative action.
The immediate consequences for Yuanchuang are likely to be reputational and operational. Public naming on a CCTV consumer‑rights programme can prompt local enforcement, client withdrawals and investor reevaluation. For the broader sector, the case underscores investor and patient risk: early‑stage firms that rely on aggressive marketing rather than robust, reproducible science face sharp downside when regulators or media expose shortcomings. Patent rejections also shape the competitive landscape by keeping contested methods and formulations outside exclusive control, which can compress valuations or drive consolidation.
For international observers, the episode is a reminder that China’s biotech ecosystem remains a mix of high‑quality research and underregulated commercial activity. As the scientific community pushes exosome research forward, regulators and investors will increasingly demand transparent data and legitimate intellectual‑property positions before conferring trust or capital. The fate of smaller players such as Yuanchuang will turn not only on media scrutiny but on whether they can meet those demands with credible science and compliant products.